AR097590A1 - Métodos para tratar el síndrome del x frágil y trastornos relacionados - Google Patents
Métodos para tratar el síndrome del x frágil y trastornos relacionadosInfo
- Publication number
- AR097590A1 AR097590A1 ARP140103351A ARP140103351A AR097590A1 AR 097590 A1 AR097590 A1 AR 097590A1 AR P140103351 A ARP140103351 A AR P140103351A AR P140103351 A ARP140103351 A AR P140103351A AR 097590 A1 AR097590 A1 AR 097590A1
- Authority
- AR
- Argentina
- Prior art keywords
- fragile
- syndrome
- metadoxine
- treat
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para tratar o aliviar un síntoma del Síndrome del X Frágil o un trastorno relacionado, que comprende administrar a un sujeto que lo necesite una composición que comprende metadoxina. Reivindicación 2: El método de acuerdo con la reivindicación 1, que comprende administrar una dosis diaria total de metadoxina de entre 100 y 3.000 mg. Reivindicación 3: El método de acuerdo con la reivindicación 1, en donde la metadoxina se administra diariamente, una vez cada dos días, o semanalmente. Reivindicación 4: El método de acuerdo con la reivindicación 1, en donde las metadoxina se administra en una, dos o tres formas de dosis por día. .Reivindicación 9: El método de acuerdo con la reivindicación 1, en donde el sujeto tiene Síndrome del X Frágil o un Trastorno del Espectro de Autismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875384P | 2013-09-09 | 2013-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097590A1 true AR097590A1 (es) | 2016-03-23 |
Family
ID=52626174
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103352A AR097591A1 (es) | 2013-09-09 | 2014-09-08 | Métodos para determinar la respuesta a la terapia |
| ARP140103351A AR097590A1 (es) | 2013-09-09 | 2014-09-08 | Métodos para tratar el síndrome del x frágil y trastornos relacionados |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103352A AR097591A1 (es) | 2013-09-09 | 2014-09-08 | Métodos para determinar la respuesta a la terapia |
Country Status (2)
| Country | Link |
|---|---|
| US (4) | US20150073023A1 (es) |
| AR (2) | AR097591A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| EP4415707A1 (en) * | 2021-10-13 | 2024-08-21 | Emory University | Uses of inhibitors of yth domain family proteins in the management of cognitive or developmental disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131856B (it) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
| WO2002043507A2 (en) | 2000-11-30 | 2002-06-06 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| CA2766107A1 (en) | 2009-06-25 | 2010-12-29 | Alcobra Ltd. | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
| TW201606304A (zh) | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 測定治療反應之方法 |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
-
2013
- 2013-09-26 US US14/038,258 patent/US20150073023A1/en not_active Abandoned
-
2014
- 2014-09-08 AR ARP140103352A patent/AR097591A1/es unknown
- 2014-09-08 AR ARP140103351A patent/AR097590A1/es unknown
- 2014-09-09 US US14/917,171 patent/US9851355B2/en not_active Expired - Fee Related
- 2014-09-09 US US14/917,169 patent/US9851354B2/en not_active Expired - Fee Related
-
2015
- 2015-08-05 US US14/819,013 patent/US20150335629A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160193199A1 (en) | 2016-07-07 |
| AR097591A1 (es) | 2016-03-23 |
| US20150073023A1 (en) | 2015-03-12 |
| US20150335629A1 (en) | 2015-11-26 |
| US20160216265A1 (en) | 2016-07-28 |
| US9851355B2 (en) | 2017-12-26 |
| US9851354B2 (en) | 2017-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000051A (es) | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CL2017003005A1 (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| CR20160170A (es) | Moduladores del factor del complemento b | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| PE20230735A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| BR112018004680A2 (pt) | método de tratamento de distúrbios de desenvolvimento | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| EA201591450A1 (ru) | Фармацевтический состав, содержащий гликозаминогликан | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| AR097590A1 (es) | Métodos para tratar el síndrome del x frágil y trastornos relacionados | |
| EA201690445A1 (ru) | Лечение рака | |
| EA201591603A1 (ru) | Новые терапевтические комбинации миртазапина для применения при болевых расстройствах | |
| EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| PH12016502284A1 (en) | Cough medicine containing ambroxol hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |